VNT 101
Alternative Names: VNT-101Latest Information Update: 16 Oct 2023
Price :
$50 *
At a glance
- Originator Novartis
- Developer Via Nova Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Influenza A virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Influenza A virus infections
Most Recent Events
- 21 Sep 2023 Preclinical trials in Influenza A virus infections in USA (unspecified route), prior to September 2023
- 21 Sep 2023 US FDA approves IND application for VNT 101 in Influenza A virus infections
- 21 Sep 2023 Via Nova Therapeutics plans a clinical trial for VNT 101 for Influenza A virus infections in USA